15 high-performance-computing Fellowship positions at University of Birmingham in United Kingdom
Sort by
Refine Your Search
-
Specification PhD (or near to completion) in high energy particle physics Experience with operation and use of Roman pot-based near-beam spectrometers Experience with analysis of data from Roman pot-based near
-
period of growth: major investment from the University will deliver a state-of-the-art research building (opening in 2023/24), and new multi-million pound high-performance computing facilities, which will
-
a specified range of activities within an established research programme and/or specific research project. We are looking for a Research Fellow to work in the area of polymer characterisation
-
diffraction and computed tomography experiments, including Rietveld refinement. A track record of high-quality research outputs and a demonstrable commitment to research excellence. Experience in
-
of processes during heavy precipitation events over India. Implement the ML postprocessing methods on high performance computing systems in a way that is suitable for operational use. Implement and test
-
dedicated to open, inclusive and inspiring research spaces for academics and their collaborators. In addition, the University of Birmingham offers exceptional High Performance Computing facilities, including
-
Birmingham Professional programme which provides all professional services staff with development opportunities and the encouragement to reach their full potential. With almost 5,000 professional services jobs
-
administer new play-based measures of executive functioning. The Research Fellow will lead on project initiation, participant recruitment, data collection, data management and analysis, report writing
-
of the responsibilities outlined below. Perform research and collect data in the specified area to a high level of competency and quality Maintain a high level of knowledge of the immediate and surrounding literature
-
(HPB). The medical oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor